Kalaris Therapeutics, Inc. (NASDAQ:KLRS) Financings

Kalaris Therapeutics, Inc.

Financings

RaiseDate
Private placement of common stock and pre-funded warrants
Announced: about US$50M · US$10 a share · Morgan Stanley +2
Dealers: Morgan Stanley (co-lead), Leerink Partners (co-lead), William Blair
Buyers: ADAR1 Capital Management; Coastlands Capital; Invus; RTW Investments; Samsara BioCapital; Woodline Partners LP
Use of proceeds: Advance clinical development of TH103 for neovascular AMD, working capital and general corporate purposes
Dec 17, 2025

Read by 6ix AI from the company's releases